Drug Profile

Agalsidase beta biosimilar - JCR Pharmaceuticals/GSK

Alternative Names: Agalsidase Beta BS I.V. Infusion [JCR]; Alpha-galactosidase A - JCR/GSK; JR-051

Latest Information Update: 02 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator JCR Pharmaceuticals
Class Galactosidases; Glycoproteins; Isoenzymes; Recombinant proteins
Mechanism of Action Alpha-galactosidase replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Fabry's disease

Most Recent Events

19 Jun 2020 Efficacy and adverse events data from a phase II/III trial in Farbry's disease released by JCR Pharmaceuticals
30 Nov 2018 Launched for Fabry's disease in Japan (IV) - First global launch
27 Sep 2018 Registered for Fabry's disease in Japan (IV, Infusion) - First Global Approval

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com